Longeveron reports ELPIS II misses primary endpoint; to analyze data, explore strategic options

Longeveron announced ELPIS II topline results showing the Phase 2b trial of laromestrocel in HLHS did not meet its primary endpoint of RVEF improvement at 12 months.Key Highlights:Original SEC Filing: Longeveron Inc. [ LGVN ] - 8-K - Sep. 23, 2026This is an AI-powered summary. It may contain inaccu…